Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 3/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22968444 | 1.00 | ADORA3 (0.47) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL24855826 | 0.82 | ADORA3 (0.43) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL23906498 | 0.82 | POLG (0.53) | PNP | |
| SCHEMBL23867000 | 0.82 | POLG (0.53) | PNP | |
| SCHEMBL9667894 | 0.80 | ADORA3 (0.46) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL442295 | 0.80 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL27745728 | 0.80 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL25968172 | 0.80 | KDM4E (0.52) | TK1TSHRMEN1ALDH1A1KMT2A | |
| SCHEMBL28384881 | 0.80 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL28707584 | 0.80 | TK1 (0.46) | ADORA3TK1PNPBLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922637-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Pharmaceutica NV (BE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Biopharma, Inc. | 2021-04-01 | — | — | US | disclosed |
| US-20210040483-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | Janssen Biopharma, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2019175260-A2 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE IN TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | WO | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | ADORA3 985/4885TK1 139/4885PNP 65/4885 |
| US-20210040483-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | ADORA3 897/4885TK1 181/4885PNP 70/4885 |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | MAPT, PSEN2, NSUN2 | ADORA3 921/4885TK1 353/4885PNP 334/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | ADORA3 985/4885TK1 139/4885PNP 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.